The Filing Desk

Cue Biopharma vs Verastem

Cue Biopharma CUE · Verastem VSTM · Pharmaceuticals

Verastem reported revenue of $31 million in fiscal 2025, about the same as Cue Biopharma's $28 million in fiscal 2025. Cue Biopharma's revenue grew 195.8% in its latest year, and Verastem's grew 209.1%. Cue Biopharma had an operating margin of -96.7%, against -550.3% at Verastem.

Side by side

Cue BiopharmaVerastem
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$28M$31M
Revenue growth195.8%209.1%
Revenue growth a year, last 5 years53.8%−19.0%
Gross margin——
Operating margin−96.7%−550.3%
Net margin−96.8%−677.6%
Free cash flow−$22M—
Free cash flow margin−79.6%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count68.2%94.1%
Last close$4.50$6.86
P/E at the last close——
Insider trades, last 12 monthsbought $99,719, sold $2.0 millionsold $680,195
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cue BiopharmaVerastem
Operating margin
Percent of revenue
Cue BiopharmaVerastem
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cue BiopharmaVerastem

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cue Biopharma and Verastem pages.